What is it about?

GLP-1RA and SGLT-2i may slow frailty progression through mechanisms independent of cardiovascular benefits.

Featured Image

Read the Original

This page is a summary of: Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Frailty Progression in Older Adults With Type 2 Diabetes, Diabetes Care, November 2025, American Diabetes Association,
DOI: 10.2337/dc25-1031.
You can read the full text:

Read

Contributors

The following have contributed to this page